US2022096465A1PendingUtilityA1
Use of levocetirizine and montelukast in the treatment of traumatic injury
Assignee: INFLAMMATORY RESPONSE RES INCPriority: Mar 13, 2013Filed: Jul 27, 2021Published: Mar 31, 2022
Est. expiryMar 13, 2033(~6.6 yrs left)· nominal 20-yr term from priority
Inventors:Bruce Chandler May
A61K 31/558A61K 31/5575A61P 43/00A61K 31/495A61K 31/7056A61K 31/496A61K 31/505A61K 31/635A61K 31/5383A61K 31/546A61K 31/47A61P 31/04A61K 31/43A61K 31/424A61K 31/65A61K 45/06A61K 31/407A61K 38/14A61K 31/7052A61P 11/00A61P 25/00A61K 31/431A61P 29/00A61P 9/10
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating traumatic injury or a symptom of traumatic injury in a patient in need thereof comprising administering an effective amount of a combination of levocetirizine and montelukast.
2 . The method of claim 1 , wherein the combination is administered at the onset of symptoms.
3 . The method of claim 1 , wherein the combination is administered at the time of diagnosis.
4 . The method of claim 1 , wherein the combination is administered in a sequential manner.
5 . The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.
6 . The method of claim 1 , further comprising the administration of an additional active agent.
7 . The method of claim 6 , wherein the additional active agent is selected from the group consisting of an antibiotic, antiviral, anti-parasitic, antifungal, vasopressor, diuretic, anticoagulant, anti-seizure medication, proton pump inhibitor, H2 receptor antagonist, antipyretic agent, anti-inflammatory drug, anti-neoplastic drug, and combinations thereof.
8 . The method of claim 6 , wherein the additional active agent is an antibiotic selected from the group consisting of vancomycin, meropenem, amoxicillin/beta clauvulanic acid, levofloxacin, piperacillin/tazobactam, ceftriaxone, clindamycin, azithromycin, trimethoprim/sulfamethoxazole, doxycycline or combinations thereof.
9 . The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.
10 . The method of claim 1 , wherein the levocetirizine and montelukast are administered by the same route.Join the waitlist — get patent alerts
Track US2022096465A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.